Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789459 | 0.90 | MAPK1 (0.68) | SMN1; SMN2ALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL8789867 | 0.89 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL8789913 | 0.87 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL8790649 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL8789438 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1RAB9ANPC1MAPK1 | |
| SCHEMBL8790726 | 0.78 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1LMNARAB9AMAPK1 | |
| SCHEMBL13056612 | 0.77 | MAOB (0.56) | ALDH1A1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL11133530 | 0.76 | PKM (0.64) | SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL3864570 | 0.76 | PTGS2 (0.59) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL13056615 | 0.76 | KMT2A (0.61) | ALDH1A1LMNAKMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0569380-A1 | ACRIDINE DERIVATIVES. | GLAXO LAB SA (FR) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012132-A1 | ACRIDINE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |